Health Technology Assessment

All Items

• Budget Impact Analysis of prolonged-release buprenorphine depot-formulation for the management of patients affected by opioid use disorder

  Michele Basile, Lorenzo Somaini, Americo Cicchetti

  96-104

  DOI: https://doi.org/10.33393/grhta.2021.2237

• Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemia

  Michele Basile, Filippo Rumi, Americo Cicchetti

  87-95

  DOI: https://doi.org/10.33393/grhta.2021.2238

• Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

  Mario Boccadoro, Patrizia Berto, Sara Bringhen, Elena Zamagni, Patrizia Tosi, Nicola Cascavilla, Nicola Giuliani, Donato Mannina, Renato Zambello, Francesca Patriarca, Vittorio Montefusco, Mariella Grasso, Francesco Di Raimondo, Massimo Offidani, Maria Teresa Petrucci, Pellegrino Musto

  80-86

  DOI: https://doi.org/10.33393/grhta.2021.2245

• Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

  Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi

  69-79

  DOI: https://doi.org/10.33393/grhta.2021.2267

• Author’s reply to comments on “Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain”

  Néboa Zozaya

  68

  DOI: https://doi.org/10.33393/grhta.2021.2272

• Comments on "Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain"

  David Gomez

  67

  DOI: https://doi.org/10.33393/grhta.2021.2261

• Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy

  Roberto Ravasio, Antonio Costanzo, Silvia Antonelli, Alessia Maiorino, Serena Losi

  53-57

  DOI: https://doi.org/10.33393/grhta.2021.2222

• The Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment

  Stefano Fagiuoli, Matteo Ruggeri, Filipa Aragao, Rob Blissett

  58-66

  DOI: https://doi.org/10.33393/grhta.2021.2183

• Cost-effectiveness analysis of caplacizumab in the new standard of care for immune Thrombotic Thrombocytopenic Purpura in Italy

  Giovanni Di Minno, Roberto Ravasio

  43-52

  DOI: https://doi.org/10.33393/grhta.2021.2191

• Costs of the management of hemophilia A with inhibitors in Spain

  Santiago Bonanad, María Teresa Álvarez, Ramiro Núñez, José Luis Poveda, Beatriz Gil, Elena Ruíz-Beato, Ana Durán, Yoana Ivanova, Inés Pérez-Román, Almudena González-Domínguez

  35-42

  DOI: https://doi.org/10.33393/grhta.2021.2234

• Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital

  Marco Chiumente, Alberto Russi, Federica Todino, Daniele Mengato, Marina Coppola, Melania Rivano, Angelo Claudio Palozzo, Claudio Jommi

  29-34

  DOI: https://doi.org/10.33393/grhta.2021.2202

• A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen

  Sergio Iannazzo

  14-21

  DOI: https://doi.org/10.33393/grhta.2021.2193

• Continuity of care between hospital pharmacies and community pharmacies, and costs avoided: a pilot experience in times of COVID-19 in Spain

  Néboa Zozaya, Almudena González-Domínguez, Natividad Calvente, Rita de la Plaza, Ana Herranz, Antonio Blanes, Miguel Tamayo

  8-13

  DOI: https://doi.org/10.33393/grhta.2021.2215

• Metastatic renal cancer: real-world evidence from a large Italian claims database

  Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Silvia Calabria, Anna Capponcelli, Antonella Pedrini, Maurizio Marangolo, Immacolata Esposito, Carmine Pinto, Nello Martini

  1-7

  DOI: https://doi.org/10.33393/grhta.2021.2178

• Cost of illness of cutaneous squamous cell carcinoma (CSCC)

  Andrea Marcellusi, Chiara Bini, Ketty Peris, Paolo Antonio Ascierto, Francesco Saverio Mennini

  148-153

  DOI: https://doi.org/10.33393/grhta.2020.2171

• Cost-effectiveness of adding psychomotor therapy to a multidisciplinary rehabilitation program for chronic pain

  Lia van der Maas, Judith E. Bosmans, Maurits W. van Tulder, Thomas W.J. Janssen

  124-130

  DOI: https://doi.org/10.33393/grhta.2020.2031

• Cost-effectiveness and budget impact of a lifestyle intervention to improve cardiometabolic health in patients with severe mental illness

  Anne Looijmans, Frederike Jörg, Richard Bruggeman, Robert A. Schoevers, Eva Corpeleijn, Talitha L Feenstra, Antoinette D.I. van Asselt

  131-138

  DOI: https://doi.org/10.33393/grhta.2020.2027

• Towards standardization of economic evaluation research in the youth psychosocial care sector: A broad consultation in the Netherlands

  Silvia M.A.A. Evers, Carmen D. Dircksen

  117-123

  DOI: https://doi.org/10.33393/grhta.2020.2143

• Factors influencing short-term effectiveness and efficiency of the care provided by Dutch general practice mental health professionals

  Tosca G.R. Vennemann, Ben F.M. Wijnen, Lianne Ringoir, Audry Kenter, Marja J.H. van Bon-Martens, Rob J.M. Alessie, Jasper Nuyen

  139-147

  DOI: https://doi.org/10.33393/grhta.2020.2028

• Mental health economics: the Netherlands experience

  Aileen Murphy, Antoinette D.I. Van Asselt

  115-116

  DOI: https://doi.org/10.33393/grhta.2020.2172

• Economic burden of prescriptive inadequacy in the management of osteoarthritis in Italy Il burden economico dell’inappropriatezza prescrittiva nella gestione dell’osteoartrite in Italia

  Michele Basile, Filippo Rumi, Marco Palmeri, Ivano Mattozzi, Lamberto Manzoli, Massimo Mammuccari, Sergio Gigliotti, Roberto Bernabei, Americo Cicchetti

  101-108

  DOI: https://doi.org/10.33393/grhta.2020.2130

• Cost-utility of dalbavancin in patients with non-severe ABSSSI in Italy

  Andrea Marcellusi, Chiara Bini, Maria Assunta Rotundo, Rosario Cultrera, Francesco Saverio Mennini

  92-100

  DOI: https://doi.org/10.33393/grhta.2020.2138

• Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease Analisi di budget impact di anakinra nel trattamento della Malattia di Still in Italia

  Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi

  72-80

  DOI: https://doi.org/10.33393/grhta.2020.2140

• Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

  Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi

  91

  DOI: https://doi.org/10.33393/grhta.2020.2187

• Patterns of prescription, hospitalizations and costs of herpes zoster in patients at risk, from a large Italian claims database

  Silvia Calabria, Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Antonella Pedrini, Immacolata Esposito, Pierluigi Viale, Nello Martini

  66-71

  DOI: https://doi.org/10.33393/grhta.2020.2026